Therapeutics companies developing immunotherapies, mRNA vaccines and anti-inflammatory therapies have been chosen to receive funding from Innovate UK Biomedical Catalyst. In total, thirty projects will receive a share of £17.8 ($23.5) million from Biomedical Catalyst, Innovate UK’s flagship grant funding mechanism. Biomedical Catalyst was created to help small and medium-sized businesses test and develop innovative […]
To read this content in full, you need to login.
Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!